X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, Revolution expects to conduct late-stage development of RAS(ON) inhibitor drug candidate pipeline, including RMC-6236, in multiple RAS-driven cancers.
Lead Product(s): RMC-6236
Therapeutic Area: Oncology Product Name: RMC-6236
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Revolution Medicines
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition November 09, 2023
Details:
Through the acquisition, Revolution expects to conduct late-stage development of RAS(ON) inhibitor drug candidate pipeline, including RMC-6236, in multiple RAS-driven cancers.
Lead Product(s): RMC-6236
Therapeutic Area: Oncology Product Name: RMC-6236
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Revolution Medicines
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition August 01, 2023
Details:
Under the terms of the collaboration agreement, Aurigene will lead drug discovery and pre-clinical development efforts, and EQRx will assume responsibility for clinical development, manufacturing, regulatory and commercialization efforts.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Recipient: Aurigene
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 05, 2022
Details:
Aumolertinib is a third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that targets both EGFR- sensitizing and T790M resistance mutations, with high selectivity over wild-type EGFR.
Lead Product(s): Aumolertinib
Therapeutic Area: Oncology Product Name: EQ143
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 29, 2022
Details:
The collaboration will combine Insilico's Pharma.AI platform to advance de novo small molecule design and generation with EQRx's clinical development and commercialization expertise.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Recipient: Insilico Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 24, 2022
Details:
Through the agreement, Abdul Latif Jameel Health will become EQRx’s regulatory and commercial partner for aumolertinib and sugemalimab, if approved, in selected markets throughout the Middle East region, as well as in Turkey and all of Africa.
Lead Product(s): Aumolertinib
Therapeutic Area: Oncology Product Name: EQ143
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Abdul Latif Jameel Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 22, 2021
Details:
Proceeds expand balance sheet to ~$2.0 billion and will be used for “new pharma” platforms. EQRx’s growing pipeline includes two pre-registrational oncology assets that have shown promising Phase 3 data (aumolertinib and sugemalimab), and other clinical-stage programs.
Lead Product(s): Aumolertinib
Therapeutic Area: Oncology Product Name: EQ143
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: CM Life Sciences
Deal Size: $2,000.0 million Upfront Cash: $2,000.0 million
Deal Type: Merger August 06, 2021
Details:
GEMSTONE-301 study investigating sugemalimab as consolidation therapy in patients with locally advanced, unresectable Stage III NSCLC without disease progression after either concurrent or sequential chemoradiotherapy.
Lead Product(s): Sugemalimab
Therapeutic Area: Oncology Product Name: CS1001
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: CStone Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 28, 2021
Details:
Funding accelerates development of late-stage cancer therapies which includes sugemalimab, almonertinib, EQRx’s PD-1 antibody (formerly known as CS1003) and lerociclib, a CDK4/6 inhibitor.
Lead Product(s): Sugemalimab
Therapeutic Area: Oncology Product Name: CS1001
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $500.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing January 11, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
